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Brefeldin A is a macrolide antibiotic that interferes with membrane traffic and blocks the growth of several animal viruses including vesicular 
stomatitis virus (VSV). The inhibition of VSV by brefeldin A takes place at least at two different steps during the growth cycle: the glycosylation 
of VSV G protein and the replication of viral genomes. Our results indicate that interference with membrane traffic leads not only to inhibition 
of viral protein glycosylation, but also to the blockade of virus genome replication in several cytoplasmic RNA-containing viruses. 
Brefeldin A; Vesicular stomatitis virus; RNA replication; Protein glycosylation 
1. INTRODUCTION 
Vesicular stomatitis virus (WV) is a member of the 
Rhabdoviridae family which has been well characterized 
at the molecular level [ 11. The bullet-shaped virus parti- 
cle is enveloped by a lipid bilayer [2]. After virus entry 
and partial decapsidation, the minus-strand RNA is 
first transcribed by the virion polymerases that form 
part of the nucleocapsid to produce five distinct mRNA 
molecules, each encoding a single viral polypeptide 
[3,4]. Translation of the VSV mRNAs produces five 
proteins known as N, NS, M, G and L, encoded in this 
order in the RNA genome (3’ to 5’) [3,4]. The progeny 
genomes are produced in two stages; first the genome 
is copied to produce a full-length positive strand RNA 
molecule, which represents an exact copy of the genome 
(-) RNA [3,4]. These (+) RNAs then act as templates 
for the synthesis of more genomic copies of (-) RNA 
[3,4]. Both types of RNA molecules are encapsidated in 
nucleocapsids but only the (-) RNA are assembled, 
after budding, in whole virions [l]. Although detailed 
studies have been carried out on the requirements of 
VSV transcription in cell-free systems, much less is 
known about he cellular processes that govern VSV 
RNA synthesis in intact cells [3,4]. 
We have reported that the replication of poliovirus, 
Semliki Forest virus and vesicular stomatitis virus RNA 
requires continuous synthesis of lipids to provide new 
membranes to which viral replication complexes attach 
[5-71. Thus, cerulenin an inhibitor of lipid synthesis 
diminishes viral genome replication [5-71. In addition, 
the inhibition of vesicular traffic by the antibiotic bre- 
feldin A (BFA) arrests poliovirus genome replication 
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[8,9], leading to the idea that proper assembly of func- 
tional replication complexes requires vesicular trans- 
port through the Golgi complex. 
BFA is a fungal antibiotic that blocks protein secre- 
tion and vesicular traffic. It induces a rapid disaggrega- 
tion of the Golgi complex that redistributes into the ER 
[ 10,111. Therefore, transport of proteins into post-Golgi 
compartments in the cell is potently blocked by BFA 
[ 121. Consequently, delivery of vesicular stomatitis virus 
(VSV) G glycoprotein to the plasma membrane is 
blocked by BFA [12-151. This compound prevents the 
proper glycosylation of the VSV G protein, in accord 
with the idea that transport from the ER to the Golgi 
complex is hampered. In addition to VSV, an increasing 
number of animal viruses are reported to be affected by 
this inhibitor [16-191. BFA inhibits the processing and 
transport of glycoproteins which are present in all these 
viruses. Thus, production of infectious particles of en- 
veloped viruses that mature from the plasma membrane 
or intracellularly is inhibited by this macrolide antibi- 
otic [16-191. Since BFA blocks poliovirus genome repli- 
cation [8,9], we wished to determine whether replication 
of genomes of other RNA-containing viruses is also 
affected by the inhibition of membrane traffic. We now 
report a novel mode of action of BFA against vesicular 
stomatitis virus, i.e. the blockade of genome replication, 
suggesting that proper assembly of functional replica- 
tion complexes requires vesicular transport through the 
Golgi complex. 
2. MATERIALS AND METHODS 
2.1. Cell cultures and virus 
Dulbecco-modified Eagle’s medium (DMEM) supplemented with 
10% newborn calf serum (E4D2) was used for growth and mainte- 
nance of HeLa cell cultures. 
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Vesicular Stomatitis Virus (VSV), Indiana strain, was propagated cells were treated with 0.5 ml 5% trichloroacetic acid, washed twice 
and titered in monolayers of BHK-21 cells. The VSV infections were with ethanol, dried under an infrared lamp and dissolved in 200 ~10.1 
performed at a multiplicity of infection (m.0.i.) of 50 pfu/cell in N NaOI-I/l% SDS. 150 ~1 samples were counted in a liquid scintilla- 
DMEM with 2% calf serum (E4D2). tion spectrometer. 
2.2. Antibiotics 2.6. Northern blot analysis of RNA 
Brefeldin-A was purchased from Sigma. Actinomycin D was sup- 
plied by Boehringer-Mannheim. 
2.3. Radioactive compounds 
[“SlMethionine (1220 Ci/mmol), n-[6-3H]glucosamine (20 Ci/mmol) 
and cytidine 5’-[cc’2P]triphosphate (400 mCi/mmol) were purchased 
from Amersham. 
2.4. Analysis of proteins by polyacrylamide gel electrophoresis and au- 
toradiography 
HeLa cell monolayers were infected as indicated in E4D2. Adsorp- 
tion was allowed to continue for 60 min at 37°C. At the times indi- 
cated, proteins were labelled by the addition of 20 ,KYml 
[“Slmethionine contained in methionine-free DMEM. To label 
glycoproteins with [3H]glucosamine, glucose-free DMEM supple- 
mented with pyruvic acid was used. After 1.5 h of incubation with the 
radioactive medium, the label was removed and the cells were har- 
vested in 0.1 ml of buffer containing 62.5 mM Tris-HCl pH 6.8, 2% 
SDS, 0.1 M dithiothreitol, 17% glycerol and 0.024% Bromophenol 
blue. Samples were sonicated at 12 Hz and boiled for 5 min. The 
samples were electrophoresed overnight at 80 v in PAGE-SDS. 
Viral RNA synthesis was studied in HeLa cell monolayers grown 
in 60 mm dishes and infected with VSV at a m.o.i. of 50 PFU/cell. BFA 
was added at the times indicated. The cells were lysed in a buffer 
containing 10 mM Tris-HCl @H 7.8), 1 mM EDTA, 150 mM NaCl 
and 0.65% Nonidet P-40. After removal of nuclei by low speed centrif- 
ugation, supematants were mixed with an equal volume of a butTer 
containing 20 mM Tris-HCl @H 7.8), 350 mM NaCl, 20 mM EDTA 
and 1% SDS. Samples were extracted with a mixture of phenol/chlo- 
roform/isoamyl alcohol (24:24:1, v/v/v) and RNA was precipitated 
with 2 vol. of ethanol. 5 pug of denatured RNA were subjected to 
electrophoresis n a 1.2% agarose/formaldehyde g l and transferred to 
nitrocellulose filters. RNA samples immobilized on nitrocellulose 
were hybridized under standard conditions to plus or minus strand- 
specific M gene RNA probes generated by in vitro transcription of a 
cDNA of the M gene of VSV flanked by the T7 and T3 promotors 
(kindly provided by Dr. R.R. Wagner, University of Virginia). 
3. RESULTS 
3.1. Effects of brefeldin A on VSV translation 
2.5. Incorporation of [‘H]uridine into RNA 
Monolayers of 5 x 10’ HeLa cells were infected with VSV at a m.o.i. 
of 50 in the presence of 5 &ml actinomycin D. 10 @i/ml of 
[5’-‘Hluridine were added at the indicated times. After a 60 min la- 
belling period the medium containing the label was discarded, and the 
To analyze the effect of brefeldin A on vesicular sto- 
matitis virus protein synthesis, different concentrations 
of this antibiotic were added at different times post- 
infection and proteins were labelled from 6 to 7 h.p.i. 
When brefeldin A is added after virus entry (0 h.p.i.) or 
VSV-INFECTED 
UNINFECTED (0) (2) (4) 
BFA addition 
(h p.i.) 
PAI 0 2 5 10 0 2 5 10 2 5 10 2 5 10 
-L 
Fig. 1. Effects of brefeldin A (BFA) on VSV protein synthesis. At the times indicated, different concentrations of BFA were added to VSV-infected 
HeLa cells (m.o.i. 50 PFU/cell). Where indicated, BFA was also added to uninfected cells after mock infection. Proteins were labelled for one hour 
with radioactive methionine at 6 h.p.i. and analyzed as described above. The arrow shows the cellular protein induced by BFA. The migration 
of VSV proteins are also indicated. 
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Fig. 2. Effect of BFA on RNA synthesis in both control and VSV-infected cells. (A) Time-course of [3H]uridine incorporation in uninfected HeLa 
cells. Uninfected HeLa cells treated with 5 &ml BFA from time ‘0’ (stippled bars), or treated with 5 &ml actinomycin D from time ‘0’ (black 
bars), or with both antibiotics (hatched bars) were labelled at the times indicated with 10 .Ki/ml [‘H]uridine for 60 min. Data are presented as 
percentage of control cells (untreated and uninfected). (B) Time-course of [3H]uridine incorporation n VSV-infected HeLa cells. HeLa cells infected 
with VSV (m.o.i. 50 pfu/cell) were incubated in the presence of 5 pug/ml actinomycin D (black circles). 5 @ml BFA were added at 0 (open circles), 
2 (open triangles) or 4 h.p.i. (open squares). Cultures were labelled with 10 @/ml [‘Hluridine for 60 min and the radioactivity in viral RNA was 
estimated as described in section 2. (C) Northern-blot analysis of RNA from VSV-infected cells. RNA was extracted from VSV-infected HeLa cells 
and the level of M gene mRNA and RF RNA was estimated by using two complementary riboprobes hybridizing with the plus or minus strand 
of the M gene, respectively. The figure shows the kinetics of VSV RNA accumulation in virus-infected cells at hours 6, 7 and 8 p.i. 5 &ml BFA 
was added when indicated at 0,2 or 4 h.p.i. and RNA was extracted at 7 h.p.i. RF, replicative form; M-mRNA, messenger RNA for M protein. 
even at 2 h.p.i. there is a substantial reduction of viral 
protein synthesis (Fig. 1). This inhibition of VSV trans- 
lation is lower when BFA is added later (4 h.p.i.), sug- 
gesting that this antibiotic does not have a direct effect 
on viral protein synthesis. As a control, the action of 
BFA on cellular translation was tested. Fig. 1 shows 
that incubation of HeLa cells with the macrolide antibi- 
otic for six hours does not interfere with cellular trans- 
lation, although there is a clear induction of a 70 kDa 
protein (Fig. 1). 
3.2. Brefeldin A blocks WV RNA synthesis 
After entry of vesicular stomatitis virus into cells and 
uncoating, the viral nucleocapsid transcribes the nega- 
tive strand RNA genome to generate the viral mRNAs 
that participate in early gene expression. The proteins 
thus made are involved in the replication of the genome, 
that in turn, will be used as template to generate more 
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mRNAs. To assay the effect of BFA on VSV transcrip- 
tion and the replication of genomes we first measured 
the incorporation of [3H@uidine in VSV-infected HeLa 
cells in the presence of actinomycin D to inhibit cellular 
but not viral RNA synthesis. An increase in viral RNA 
synthesis is observed from the fifth h.p.i. peaking at the 
seventh h.p.i. Addition of BFA at 0, 2 or 4 h.p.i. leads 
to a reduction in VSV RNA synthesis (Fig. 2B). Some 
[3H]uridine incorporation is observed even when BFA 
was present from 0 h.p.i. perhaps indicating that tran- 
scription of viral RNA from the input VSV nucleo- 
capsid occurs. On the other hand, BFA significantly 
reduced viral RNA synthesis even when added 4 h.p.i., 
suggesting that this is one of the targets of BFA action 
on VSV growth. The inhibition of [3H]uridine incorpo- 
ration by BFA was selective for viral RNA synthesis 
and almost no effect on cellular RNA synthesis was seen 
even after seven hours of incubation with the antibiotic 
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Fig. 3, Effect of BFA on glycosylation of VSV G protein. HeLa cells 
were infected with VSV (m.o.i. 50 PFU/~~). Different ~n~tra~ons 
of BFA were added at 5 h.p.i. Thirty minutes later, proteins were 
labelled for 1.5 h with radioactive methionine (20 ,uCiiml) or glu- 
cosamine (20 ~Ciiml). The proteins were analyzed by SDS-PAGE as 
described in section 2. The migration of VSV G protein is indicated. 
(Fig. 2A). To analyze the effect of BFA on VSV RNA 
synthesis by Northern blot hybridization the RNA was 
extracted from untreated cells at different times post- 
infection, or at 7 h.p.i. from cells treated with BFA from 
0,2 or 4 h.p.i. Northern blots were hybridized with plus- 
and minus-strand specific probes covering the M gene 
region of the VSV genome to detect the RF RNA and 
mRNA respectively. Fig. 2C shows that BFA reduces 
the amount of RF RNA or viral mRNA, particularly 
if the compound was added at 0 h.p.i. Notably, some 
synthesis of M mRNA is detected when BFA is present 
from the beginning of infection suggesting that the early 
transcription of viral mRNA may not be inhibited by 
the antibiotic. The presence of this amount of mRNA 
could account for the partial synthesis of viral proteins 
when BFA is added at 0 h.p.i. (Fig. 1). 
3.3. Effect of BFA on VW G protein glycosylution 
VSV possesses a single glycoprotein (G) which is in- 
serted into the lipid bilayer that surrounds the virion 
particles. Glycosylation of the G protein was analyzed 
by labelling with radioactive glycosamine from 5.5 to 
7 h.p.i. in the presence of two different concentrations 
of BFA (Fig. 3). In agreement with the results shown 
in Fig. 1, BFA had no significant effects on viral protein 
synthesis when added late during infection, whereas the 
antibiotic strongly decreased the incorporation of gly- 
cosamine into VSV G protein. 
These results are in agreement with previous findings 
and indicate that glycosylation is another target of BFA 
activity on VW. 
4. DISCUSSION 
The maturation of membrane proteins in eukaryotic 
cells involves passage through the ER, and sequential 
migration through the cis- medial- and trans-compart- 
ments of the Golgi complex to an organelle known as 
the trans-Golgi network (TGN) [2&23]. Several routes 
can be followed by the proteins from the Golgi appara- 
tus, including incorporation into the plasma membrane, 
transport to endosomes, lysosomes, etc. 120-231. Recent 
results with poliovirus indicate that an intact vesicular 
system is required for the formation of functional RNA 
replication complexes, implying that the replication of 
viral genomes in the cytoplasm of eucaryotic cells is 
connected with the formation of new membranous 
structures [5--g]_ Our present findings show that, in ad- 
dition to poliovirus, VSV RNA synthesis is also inhib- 
ited by BFA, lending support to the concept that cyto- 
plasmic genome replication of RNA-containing animal 
viruses is functionally coupled to vesicular transport. In 
addition to this effect, it has been well doc~ented that 
brefeldin A also interferes with the glycosylation of pro- 
teins [12,13]. Cellular and viral glycoproteins must 
travel through the vesicular system to be properly glyco- 
sylated, a process blocked by BFA. 
Thus, at least two different targets of action of BFA 
exist in the case of VSV, genome replication and the 
glycosylation of protein G. Both events may have con- 
sequences for virus budding, because the formation of 
nucleocapsids and the proper location of G protein in 
the plasma membrane are necessary for the formation 
of new virions to occur. 
Our present findings show that not only positive- 
stranded viruses, such as poliovirus, but also a negative- 
stranded virus such as VSV require an intact vesicular 
system for virus genome replication. The exact under- 
standing of the molecular mecha~sms that govern the 
interaction of replication complexes with membranes 
will shed light on the synthesis of viral genomes and 
provide a rationale for development of antiviral agents 
against hese viruses. The specificity of such an antiviral 
approach could rely upon the selective inhibition of 
viral proteins that connect the RNA replication com- 
plexes with cellular membranes. 
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